The treatment of #PE has been plagued by high acute mortality rates. Current risk stratification relies on #thrombolytics which carry a significant bleeding risk. #medthread#FLASH
2/11
The #FlowTriever System, the first FDA-cleared mechanical thrombectomy system for #PE, is purposely designed to capture and remove large clot burden from big vessels in a single session without the need for tPA or prolonged #ICU stay. #medthread#FLASH
3/11
The #FLASH registry is a prospective, multicenter study designed to evaluate the safety and effectiveness of #FlowTriever in a real-world patient population. #medthread
4/11
Interim analysis of the first 230 patients highlights a real-world #PE population, with 93% IM-risk/submassive and 7% high-risk/massive and nearly 40% with a contraindication to #lytics. (So these are sick pts!) #medthread#FLASH
5/11
Access site complications were rare, which speaks to the safety of large-bore venous access. There was low adjunctive therapy use and the *median* ICU length of stay was 0 days. #medthread#FLASH
6/11
Interim #FLASH results highlight:
💥0% mortality through 48 hrs
💥0.4% mortality through 30 days
💥MAE rate of 1.3%.
The mortality data compares favorably to the recent @PERTConsortium mortality rate of ~10% across intermediate- and high-risk PE. #medthread
7/11
Pts had on-table improvements in heart rate, mean PA pressure, cardiac index, and other #hemodynamic measures.
Looking at long-term outcomes, patients showed improved symptomology and cardiac size/function through 30 days. #medthread#FLASH
9/11
The #FLASH interim results are extremely encouraging, reinforcing the safety profile of #FlowTriever#thrombectomy for PE, with patients seeing on-table improvement of vitals and hemodynamics and continuing to improve through 30 days. #medthread#FLASH
10/11
Thanks to all of the investigators, including national PI @CatalinPToma, for this important data set for the field of #PE. #medthread#FLASH
11/11
• • •
Missing some Tweet in this thread? You can try to
force a refresh